We will be embarking on the following clinical trial:
Protocol number title: AMC-099 A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program
|PI||Interventional / Observational||Closed/ Ongoing||Start/
|Dr Carla Chibwesha||Intervention||Pending||AIDS Malignancy Consortium||AIDS Malignancy Consortium|
The upcoming COVENANT study, chaired by CHRU researchers and sponsored by the AIDS Malignancies Consortium (AMC),will investigate whether women at high risk for recurrent cervical disease should receive the HPV vaccine in addition to standard treatment for cervical pre-HIV-cancers. The study will enrol 536 women from seven sites in Africa including South Africa. Women will be monitored for two years.